Skip to main content

Table 4 Reclassification of scoring systems and overall survival

From: Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

Scoring grades

Patients (n)

Death events (n)

Median OS months (95% Cl)

 

Original A to new A (AA)

71

50

12.7 (10.3–33.2)

 

Original A to new B (AB)

29

23

12.0 (7.1–37.2)

 

Original A to new C (AC)

8

6

7.5 (6.0–NA)

 

Original B to new A (BA)

8

7

7.9 (7.4–NA)

 

Original B to new B (BB)

34

30

8.7 (5.8–11.7)

 

Original B to new C (BC)

28

21

5.2 (3.9–NA)

 

Original C to new A (CA)

0

0

NA

 

Original C to new B (CB)

4

4

2.3 (1.5–NA)

 

Original C to new C (CC)

34

24

6.8 (4.1–39.3)

 

Scoring grades

HR (95%Cl)

p

 AA

1.00 (referent)

 

 AB

1.23 (0.75–2.01)

0.42

 AC

1.33 (0.57–3.10)

0.51

 BA

1.19 (0.53–2.68)

0.67

 BB

1.76 (1.12–2.78

0.015

 BC

1.71 (1.02–2.85)

0.04

 CB

9.58 (3.37–27.28)

< 0.001

 CC

1.43 (0.88–2.33)

0.15

 BB

1.00 (referent)

 

 AA

0.57 (0.36–0.90)

0.015

 AB

0.70(0.40–1.20)

0.19

 AC

0.75 (0.31–1.81)

0.53

 BA

0.68 (0.29–1.58)

0.37

 BC

0.97 (0.55–1.70)

0.91

 CB

5.44 (1.88–15.78)

0.002

 CC

0.81 (0.47–1.39)

0.45

 CC

1.00 (referent)

 

 AA

0.70 (0.43–1.14)

0.15

 AB

0.86 (0.48–1.52)

0.6

 AC

0.93 (0.38–2.27)

0.87

 BA

0.84 (0.35–1.98)

0.68

 BB

1.23 (0.72–2.11)

0.45

 BC

1.2 (0.66–2.15)

0.55

 CB

6.7 (2.27–19.81)

< 0.001

  1. The log-rank test was used to compare overall survival, p<0.05 was considered as significant
  2. Abbreviations: OS overall survival, CI confidence interval, NA not applicable, i.e., upper bound cannot be computed